Acrobiosystems Co Ltd. Stock Analysis 301080.SZ

ACROBiosystems Co., Ltd. provides key biological reagent products and technical services such as recombinant proteins. The company is headquartered in Beijing, Beijing and currently employs 926 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.